This roundtable discussion looks at the advantages and disadvantages of overall survival and progression free survival as primary end points of clinical trials. The discussants also talk about how the primary endpoints for clinical trials are decided and by whom.

Supported by an educational grant from Eisai Pharma Europe Ltd.

Click on the links below to see more from the participants in this round table debate:

Prof. David Cameron chairs a round table debate on clinical trial design and comparator arms.
Prof. David Cameron participates in a round table debate on targeted therapies for metastatic breast cancer.
Prof. Hilary Calvert speaks to ecancertv about the lifetime achievement award he received from the British Oncological Association.